ALB and non-small cell lung carcinoma: In a study of 93 pre-treated advanced NSCLC patients in the United States who received ICI monotherapy, never-smokers or those who smoked fewer pack years, more involved metastatic sites, more prior therapies and a lower mean albumin level were reported as factors predictive of primary resistance to ICI therapy [17].